ArticleFrontiers in microbiology2021
Prevalence of ExoY Activity in
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Genomic comparison and phenotypic characterization ofmSystems · 2026Article
- Essential role of cytochromeFrontiers in cellular and infection microbiology · 2026Article
- Structural and functional insights into Pseudomonas aeruginosa's secretion systems 1-6: regulation, role in microbial keratitis and drug targets.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- A conserved virulence backbone and heterogeneous type III secretion effector profiles in historical canine otitis-associatedFrontiers in veterinary science · 2026Article
- Interplay between T3SS effectors, ExoY activation, and cGMP signaling in Pseudomonas aeruginosa infection.Nature communications · 2025Article
- Mapping genetic and phenotypic diversity ofbioRxiv : the preprint server for biology · 2025Article
- Cytotoxicity induced by Aeromonas schubertii is orchestrated by a unique set of type III secretion system effectors.Veterinary research · 2025Article
- The relationship between virulence and drug resistance genes inFrontiers in cellular and infection microbiology · 2025Article
- Carbapenem-resistantFrontiers in pharmacology · 2025Article
- Genomic features and fitness cost of co-existence ofFrontiers in cellular and infection microbiology · 2025Article
- Genomic virulence markers are associated with severe outcomes in patients with Pseudomonas aeruginosa bloodstream infection.Communications medicine · 2024Article
- ThePathogens (Basel, Switzerland) · 2024Article
- NLRP3 selectively drives IL-1β secretion by Pseudomonas aeruginosa infected neutrophils and regulates corneal disease severity.Nature communications · 2023Article
- Functional and structural insights into the multi-step activation and catalytic mechanism of bacterial ExoY nucleotidyl cyclase toxins bound to actin-profilin.PLoS pathogens · 2023Article
- Bacterial Nucleotidyl Cyclases Activated by Calmodulin or Actin in Host Cells: Enzyme Specificities and Cytotoxicity Mechanisms Identified to Date.International journal of molecular sciences · 2022Review
- Exotoxin S secreted by internalized Pseudomonas aeruginosa delays lytic host cell death.PLoS pathogens · 2022Article
- Modulation of the immune response by theFrontiers in cellular and infection microbiology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ExoY is among the effectors that are injected by the type III secretion system (T3SS) of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.